Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: Enhanced excitotoxic potency and selectivity

Toxicology and Applied Pharmacology

Volumn 144, Issue 1, 1997, Pages 45-55

  Willis, Colin L ^a   Dauenhauer, Danielle L ^a   Humphrey, John M ^b   Chamberlin, A Richard ^b   Buller, Amy L ^c   Monaghan, Daniel T ^c   Bridges, Richard J ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITOTOXIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PYRROLIDINE DERIVATIVE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CHEMICAL MODIFICATION; DRUG POTENCY; HIPPOCAMPUS; MALE; METHYLATION; NERVE INJURY; NEUROTOXICITY; NONHUMAN; OOCYTE; RAT; XENOPUS;

ANIMALIA;

EID: 0031148908     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8112     Document Type: Article

References (48)

1. Booth R. F. G., Clark J. B. A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain. Biochem. J. 176:1978;365-370.
2. Brewer G. J., Cotman C. W. Survival and growth of hippocampal neurons in defined medium at low density: Advantages of a sandwich culture technique or low oxygen. Brain Res. 494:1989;65-74.
3. Bridges R. J., Geddes J., Monaghan D. T., Cotman C. W. Excitatory amino acid receptors in Alzheimer's disease. Excitatory Amino Acids in Health and Disease. 1987;Wiley, Sussex. p. 321-335.
4. Bridges R. J., Stevens D. R., Kahle J. S., Nunn P. B., Kadri M., Cotman C. W. Structure-function studies onN. J. Neurosci. 9:1989;2073-2079.
5. Bridges R. J., Hatalski C., Shim S. N., Nunn P. B. Gliotoxic properties of the Lathyrus excitotoxin β-N-oxalyl-L-α,β-diaminopropionic acid (β-L-ODAP). Brain Res. 561:1991a;262-268.
6. Bridges R. J., Stanley M. S., Anderson M. W., Cotman C. W., Chamberlin A. Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomer. J. Med. Chem. 34:1991b;717-725.
7. Buller A. L., Larson H. C., Schneider B. E., Beaton J. A., Morrisett R. A., Monaghan D. T. The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J. Neurosci. 14:1994;5471-5484.
8. Choi D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
9. Choi D. W. Glutamate receptors and the induction of excitotoxic neuronal death. Prog. Brain Res. 100:1994;47-51.
10. Choi D. W., Maulucci-Gedde M., Kriegstein A. R. Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7:1987;357-368.
11. Collingridge G. L., Lester R. A. J. Excitatory amino acids receptors in the vertebrate central nervous system. Pharmacol. Rev. 41:1989;143-210.
12. Cotman C. W., Monaghan D. T., Ottersen O. P., Storm-Mathisen J. Anatomical organization of excitatory amino acid receptors and their pathways. TINS. 10:1987;273-280.
13. Debonnel G., Beauchesne L., de Montigny C. Domoic acid, the alleged "mussel toxin," might produce its neurotoxic effect through kainate receptor activation: An electrophysiological study in rat dorsal hippocampus. Can. J. Physiol. Pharmacol. 67:1989;29-33.
14. Foster A. C., Gill R., Woodruff G. N. Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8:1988;4745-4754.
15. 3. J. Neurochem. 38:1982;173-178.
16. Humphrey J. M., Bridges R. J., Chamberlin A. R. 2,3-Pyrrolidine dicarboxylates as neurotransmitter conformer mimics: Enantioselective synthesis via chelation-controlled enolate alkylation. J. Org. Chem. 59:1994;2467-2472.
17. Ishida M., Shinozaki H. Acromelic acid is a much more potent excitant than kainic acid or domoic acid in the rat spinal cord. Brain Res. 474:1988;386-389.
18. Koh J., Choi D. W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods. 20:1987;83-90.
19. 2+. Brain Res. 567:1991;342.
20. Kuhar M. J., Zarbin M. Synaptosomal transport: A chloride dependence for choline, GABA, glycine and several other compounds. J. Neurochem. 31:1978;251-256.
21. Lanthorn T. H., Hood W. F., Watson G. B., Compton R. P., Rader R. K., Gaoni Y., Monahan J. B. cis. Eur. J. Pharmacol. 182:1990;397-404.
22. Laurie D. J., Seeburg P. H. Ligand affinities at recombinantND. Eur. J. Pharmacol. 268:1994;335-345.
23. 3. Mol. Pharmacol. 15:1979;492-505.
24. Madsen U., Bang-Andersen B., Brehm L., Christensen I. T., Ebert B., Kristoffersen I. T. S., Lang Y., Krogsgaard-Larsen P. Synthesis and pharmacology of highly selective carboxy and phosphono isoxazole amino acid AMPA receptor antagonists. J. Med. Chem. 39:1996;1682-1691.
25. Mangano R. M., Schwarcz R. Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus. Brain Res. Bull. 10:1983;47-51.
26. Meldrum B. S. Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol. 3:1993;405-412.
27. Monaghan D. T., Cotman C. W. Identification and properties of N-methyl-D. Proc. Natl. Acad. Sci. USA. 83:1986;7532-7536.
28. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P. H. Hetromeric NMDA receptors: Molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
29. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 354:1991;31-37.
30. Olney J. W. Excitotoxic amino acids: Research applications and saftey implications. Filer L. J. Glutamic Acid: Advances in Biochemisty and Physiology. 1979;287-319 Raven Press, New York.
31. Olney J. W. Endogenous excitotoxins and neuropathological disorders. Lodge D. Excitatory Amino Acids in Health and Disease. 1988;337-351 Wiley, Sussex.
32. Olney J. W., Sharpe L. G., deGubareff T. Excitotoxic amino acids. Soc. Neurosci. Abstr. 1:1975;371.
33. Rothman S. M., Olney J. W. Excitotoxicity and the NMDA receptor-still lethal after eight years. TINS. 18:1995;57-58.
34. Schoepp D. D., Smith C. L., Lodge D., Millar J. D., Leander J. D., Sacaan A. I., Lunn W. H. W. D,L-(Tetrazol-5-yl)glycine: A novel and highly potent NMDA receptor agonist. Eur. J. Pharmacol. 203:1991;237-243.
35. Schoepp D. D., Lunn W. H. W., Salhoff C. R., McDonald J. W. The NMDA receptor agonist DL-(Tetrazol-5-yl) glycine is a highly potent excitotoxin. Eur. J. Pharmacol. 270:1994;67-72.
36. Sheardown M. J., Nielsen E. O., Hansen A. J., Jacobsen P., Honore T. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: A neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
37. Sheng M., Cummings J., Roldan L., Jan Y., Jan L. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature. 368:1994;144-147.
38. Shinozaki H., Ishida M., Shimamoto K., Ohfune Y. A conformationally restricted analogue of L-glutamate, the (2S,3R,4S) isomer of L-α-(carboxycyclopropyl)glycine, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord. Brain Res. 480:1989;355-359.
39. 3. J. Neurochem. 26:1976;141-147.
40. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
41. Sugihara H., Moriyoshi K., Ishii T., Masu M., Nakanishi S. Structure and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. 185:1992;826-832.
42. Westerberg E., Monaghan D. T., Cotman C. W., Wieloch T. Excitatory amino acid receptors and ischemic brain damage in the rat. Neurosci. Lett. 73:1987;119-124.
43. White M. M., Mayne K. M., Lester H. A., Davidson N. Mouse-Torpedo hybrid acetylcholine receptors: Functional homology does not equal sequence homology. Proc. Natl. Acad. Sci. USA. 82:1985;4852-4856.
44. Wieloch T. Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science. 230:1985;681-683.
45. Willis C. L., Meldrum B. S., Nunn P. B., Anderton B. H., Leigh P. N. Neuronal damage induced by β-N-oxalylamino-L-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. Brain Res. 627:1993;55-62.
46. Willis C. L., Humphrey J. M., Chamberlin A. R., Bridges R. J. Identification of a novel NMDA agonist. Soc. Neurosci. Abstr. 21:1995;1028.
47. Willis C. L., Humphrey J. M., Koch H. P., Hart J. A., Blakely T., Ralston L., Baker C. A., Shim S., Kadri M., Chamberlin A. R., Bridges R. J. L-trans. Neuropharmacology. 35:1996;531-539.
48. Wong E. H. F., Kemp J. A., Priestley T., Knight A. R., Woodruff G. N., Iversen L. L. The anticonvulsant MK-801 is a potentN. Proc. Natl. Acad. Sci. USA. 83:1986;7104-7108.